| 1/50 | Câncer Bettoni F, Inoue LT, Pires LC, Parmigiani RB, Camargo AA. Characterization of C210RF100 as a novel prostate differentiation antigen. Applied Cancer Research, São Paulo: Tecmedd, v.25, n.3, p. 116-121, 2005. ISSN 1808-5512. Disponível em: http://accamargo.phlnet.com.br/applied/ACR200525p.116-121.pdf PROSTATE; DIFFERENTIATION ANTIGEN; CHORMOSOME; IMMUNOTHERAPY |
| 2/50 | US=19 / Psco/Psq Knobf MT, Pasacreta JV, Valentine A, Mccorkle R. Chemotherapy, hormonal therapy, and immunotherapy. In: Holland JC. Psycho-oncology. New York: Oxford University, 1998. p. 277-88. CANCER; QUIMIOTERAPIA; COMBINACOES QUIMIOTERAPICAS; TERAPIA; METAS; ENDOCRINA; BIOTERAPIA; TEMAS PSICOLOGICOS; DURANTE O TRATAMENTO; APOS O TRATAMENTO; TERMINO DO TRATAMENTO; CASOS DE DOENCA PROGRESSIVA; QUALIDADE DE VIDA; ASSISTENCIA A SAUDE |
| 3/50 | US=22 / Câncer Restifo NP, Robbins PF, Rosenberg SA. Principles of immunotherapy. In: Devita Jr VT, Hellman S, Rosenberg AS. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 8ªed. Philadelphia: Lippincott Willians & Wilkins, 2008. p. 351-68. CATEGORIAS DOS TUMORES; FATORES MULTIPLOS; TERAPIAS DO CANCER; TERAPIAS ESPECIFICAS; VACINAS PEPTIDICAS; VACINAS RECOMBINANTES; MONITORIZACAO IMUNOLOGICA |
| 4/50 | US=22-A / Câncer Rosenberg SA, Dudley ME. Cancer immunotherapy. In: Devita Jr VT, Hellman S, Rosenberg AS. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 8ªed. Philadelphia: Lippincott Willians & Wilkins, 2008. p. 2979-89. |
| 5/50 | US=184 / Tese/FAP Bettoni F. Utilização dos dados de seqüências expressas na identificação e caracterização de novos antígenos tumorais Cancer/Testi. São Paulo, 2007. 125 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2007/us184.pdf
SEQUENCIAS ETIQUETAS EXPRESSAS; ANTIGENOS DE TUMORES; IMUNOTERAPIA; GENES. IDENTIFICACAO |
| 6/50 | US=18 / Pélvis Jain A, Schulick R. Vaccines and immunotherapy. In: Gearhart SL, Ahuja N. Colorectal cancer. Philadelphia: Elsevier Saunders, 2011. p. 225-38. (Early Diagnosis and Treatment of Cancer) ISBN 978-1-4160-4686-8. CANCER COLORRETAL; CANCER COLORRETAL. VACINAS; CANCER COLORRETAL. IMUNOTERAPIA; IMUNOTERAPIA. VISAO GLOBAL; IMUNOTERAPIA PASSIVA; IMUNOTERAPIA ATIVA; ANTICORPO ANTI-IDIOTIPICO; CELULAS DENDRITICAS; METASTASES |
| 7/50 | US=9 / Urologia Higano CS. Sipuleucel-T: autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 321-27. ISBN 978-1-60327-831-7. SIPULEUCEL-T; IMUNOTERAPIA CELULAR AUTOLOGA; CANCER DE PROSTATA; METASTATICO RESISTENTE A CASTRACAO; HORMONIO REFRATARIO; PROVENCE; IMUNOTERAPIA CELULAR AUTOLOGA; RESISTENTE A CASTRACAO; APC8015 |
| 8/50 | US=23-E / Câncer Tomita Y, Maruyama R, Itoi T, Bilim V. Metastatic renal cell carcinoma: use of Bcl-2 and Fas to predict responses to immunotherapy. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 137-45. ISBN 978-90-481-2917-1. CARCINOMA; METASTATICO DE CELULAS RENAIS; BCL-2 E FAS; IMUNOTERAPIA |
| 9/50 | US=4 / Ginecologia Sabbatini PJ, Chang DZ, Divgi CR, Livingston PO, Houghton AN. Immunotherapy of gynecologic malignancies. In: Barakat RR, Markman M, Randall ME. Principles and practice of gynecologic oncology. 5ªed. Philadelphia: Lippincott Williams & Wilkins, 2009. p. 113-43. ISBN 978-0-7817-7845-9. IMUNOTERAPIA DE NEOPLASIAS MALIGNAS GINECOLOGICAS; CANCER DE IMUNOLOGIA; IMUNOMODULACAO DE CITOCINAS E TERAPIA; MEDIADA POR ANTICORPOS TERAPIA DE CANCER; ANTICORPOS MONOCLONAIS; TERAPIA CELULAR ADOTIVA; VACINAS CONTRA O CANCER; LINFOCITOS T RESPOSTAS |
| 10/50 | US=8 / Cab/Pescoço Chapoval AI, Schulze DH, Strome SE. Immunotherapy for head and neck cancer. In: Snow JB Jr, Wackym PA. Ballenger's otorhinolaryngology head and neck surgery. 17ª ed. Lewiston: BC Decker, 2009. p. 1055-61. ISBN 1-55009-337-7. IMUNOTERAPIA PARA CANCER DE CABECA E PESCOCO; IMUNOTERAPIA DE CANCER; DESAFIOS PARA IMUNOTERAPIA DE CANCER; CANCER DE CABECA E PESCOCO; IMUNOTERAPIA PASSIVA DE CANCER |
| 11/50 | US=27 / Fisioterapia Koehne G. Principles of immunotherapy. In: Stubblefield MD, O'Dell MW. Cancer rehabilitation: principles and practice. New York: DemosMedical, 2009. p. 53-71. ISBN 978-19-338643-34. PRINCIPIOS DA IMUNOTERAPIA; PRINCIPIOS DA TERAPIA IMUNE CELULAR; PRINCIPIOS DA TERAPIA IMUNITARIA HUMORAL; PRINCIPIOS DE VACINAS CONTRA O CANCRO |
| 12/50 | US=50 / Câncer Lee WT, Shu S. Role of lymph nodes in immunotherapy of malignant tumors. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 391-400. ISBN 978-1-60327-086-1. GANGLIOS LINFATICOS NA IMUNOTERAPIA DE TUMORES MALIGNOS; IMUNOTERAPIA; LINFONODO; MALIGNIDADE; HIBRIDOS DE FUSAO |
| 13/50 | US=50 / Câncer Chmielowski B, Ribas A. Targeting immunological synapse: new horizons in immunotherapy for cancer. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 575-90. ISBN 978-1-60327-086-1. SEGMENTACAO SINAPSE IMUNOLOGICA; IMUNOTERAPIA PARA O CANCER; IMUNOTERAPIA; SINAPSE IMUNOLOGICA; CTLA-4; AUTO-IMUNIDADE; MELANOMA; CANCER |
| 14/50 | US=78 / Biol/Mol Guo Z. Glycoengineering of cell surface sialic acid and its application to cancer immunotherapy. In: Guo Z, Boons G-J, editors. Carbohydrate-based vaccines and immunotherapies. New Jersey: Willey, 2009. p. 313-31. (Drug Discovery and Development) ISBN 978-0-470-19756-1. |
| 15/50 | US=89 / Biol/Mol Nemunaitis JJ. Gene immunotherapy for non-small cell lung cancer. In: Walther W, Stein US. Gene therapy of cancer: methods and protocols. 2ª ed. New Jersey: Humana Press, 2009. p. 499-514. (Methods in Molecular Biology, 542) ISBN 978-1-59745-561-9. CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; IMUNOTERAPIA GENETICA |
| 16/50 | US=49-F / Câncer Mehrotra S, Mougiakakos D, Johansson CC, Voelkel-Johnson C, Kiessling R. Oxidative stress and lymphocyte persistence: implications in immunotherapy. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 197-227. ISBN 978-0-12-3744371. ESTRESSE OXIDATIVO E PERSISTENCIA DE LINFOCITOS; ESTRESSE OXIDATIVO; SUBCONJUNTOS DE LINFOCITOS; MECANISMOS DE SUSCEPTIBILIDADE DIFERENCIAL |
| 17/50 | US=10 / Urologia Assikis VJ, Jonas W, Simons JW. The promise of immunotherapy in prostate cancer: from concept to reality. In: Kirby RS, Partin AW, Parsons JK, Feneley MR. Treatment methods for early and advanced prostate cancer. New York: Informa Healthcare, 2008. p. 379-88. ISBN 978-0415-458933-1. CANCER DE PROSTATA; IMUNOTERAPIA; VACINA; TECNOLOGIA DE TRANSFERENCIA GENETICA; IMUNOTERAPIA ATIVA; CITOCINAS; IMUNOTERAPIA PASSIVA |
| 18/50 | US=105 / Câncer Lamm DL. Bacillus Calmette-Guérin immunotherapy of genitourinary cancer. In: Orentas R, Hodge JW, Johnson BD. Cancer vaccines and tumor immunity. New Jersey: Wiley-Interscience, 2008. p. 29-42. ISBN 978-0-470-07474-9. CANCER; CANCER GENITO-URINARIO; IMUNOTERAPIA; BACILO CALMETTE-GUERIN; VACINA BCG; TUBERCULOSE; CANCER DE BEXIGA; QUIMIOTERAPIA; CARCINOMA IN SITU; CANCER RENAL; CANCER DE PROSTATA; RESPOSTA IMUNE; TOXICIDADE |
| 19/50 | US=105 / Câncer Tsen SWD, Hung CF, Wu TC. Antigen-specific cancer immunotherapy: HPV-associated cervical cancer as a model system. In: Orentas R, Hodge JW, Johnson BD. Cancer vaccines and tumor immunity. New Jersey: Wiley-Interscience, 2008. p. 79-94. ISBN 978-0-470-07474-9. CANCER; IMUNOTERAPIA ANTIGENO-ESPECIFICA; CANCER CERVICAL; HPV |
| 20/50 | US=105 / Câncer Munson S, Parker J, King TH, Lu Y, Kelley V, Guo Z, Borges V, Franzusoff A. Coupling innate and adaptative immunity with yeast-based cancer immunotherapy. In: Orentas R, Hodge JW, Johnson BD. Cancer vaccines and tumor immunity. New Jersey: Wiley-Interscience, 2008. p. 131-49. ISBN 978-0-470-07474-9. |
